Navigation Links
Launching a global alliance for pharmacogenomics

Leaders at the National Institutes of Health and the Center for Genomic Medicine in Japan have signed a letter of intent creating a Global Alliance for Pharmacogenomics. The effort aims to identify genetic factors that contribute to individual responses to medicines, including rare and dangerous side effects. The results of such work will eventually help doctors optimize the safety and effectiveness of drugs for each patient.

U.S. scientists joining the alliance are members of the NIH Pharmacogenetics Research Network, a consortium of research groups that study how genetic factors influence the way drugs work in and are handled by the body.

Japanese scientists in the alliance represent the newly created Center for Genomic Medicine, a component of the RIKEN Yokohama Institute that conducts high-throughput analyses of human genes involved in diseases and drug responses.

Signers of the agreement include the directors of three of the National Institutes of Health: Jeremy M. Berg, Ph.D., director of the National Institute of General Medical Sciences; Elizabeth G. Nabel, M.D., director of the National Heart, Lung, and Blood Institute; and John E. Niederhuber, M.D., director of the National Cancer Institute.

"By bringing together our resources, we will advance the understanding of how changes in DNA affect our responses to medicines. Thus we can begin to realize the promise of personalized medicine," said Yusuke Nakamura, M.D., Ph.D., director of the Center for Genomic Medicine at RIKEN.

We expect this international agreement to speed scientific discovery and the translation of results into improved treatments for cancer, heart disease and other serious conditions, said NIH Director Elias A. Zerhouni, M.D. Ultimately, physicians worldwide will be able to tailor the treatment of each patient--one of the great frontiers of health care today.

Initial projects will focus on:

  • Understanding genetic factors that influence the effectiveness of breast cancer treatments (aromatase inhibitors)

  • Determining the optimal length of treatment for two drugs used to treat early stage breast cancer (cyclophosphamide and either doxorubicin or paclitaxel)

  • Discovering new genetic factors linked to serious side effects from certain pancreatic cancer drugs (gemcitabine and bevacizumab)

  • Exploring how genes contribute to drug-induced long QT syndrome, an irregular heart rhythm that can cause sudden cardiac arrest

  • Working with the International Warfarin Consortium to tailor initial doses of the anti-clotting drug warfarin based on the genetic profiles of patients

A steering committee will manage the alliance and will meet twice a year to discuss progress, future directions, intellectual property issues, the approval of additional members and communication with the public. Alliance members will share their data and their research results with the scientific community.

The letter of intent is available at This site also includes acknowledgements of the research centers that provided DNA samples essential to perform the work.


Contact: Alisa Machalek
NIH/National Institute of General Medical Sciences

Related biology news :

1. Regional nuclear conflict would create near-global ozone hole, says CU-Boulder study
2. At ACS national meeting, global initiative set to tackle water issues
3. Harmful algae taking advantage of global warming
4. Despite awareness of global warming Americans concerned more about local environment
5. Black carbon pollution emerges as major player in global warming
6. Speaker, judges set for Global Venture Challenge
7. Pew Institute teams with Chantecaille Cosmetics to protect global marine life
8. Smithsonian announces Global Forest Carbon Research Initiative
9. Will global warming increase plant frost damage?
10. Destruction of Sumatra forests driving global climate change and species extinction
11. U-M researchers release most detailed global study of genetic variation
Post Your Comments:
(Date:5/24/2016)... 2016 Ampronix facilitates superior patient care by providing unparalleled technology to leaders ... is the latest premium product recently added to the range of products distributed by ... ... ... LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita ... miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject of ... now. , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
Breaking Biology Technology: